

Roche, Eli Lilly to develop Elecsys Amyloid Plasma Panel for Alzheimer's

March 22, 2023—[Roche](#) has entered into a collaboration with [Eli Lilly](#) to support the development of Roche's Elecsys Amyloid Plasma Panel. If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients.

The panel measures phosphorylated tau 181 protein assay and apolipoprotein E4 assay in human blood plasma. The result is intended for consideration in conjunction with other clinical information to advise for further confirmatory testing with amyloid positron emission tomography or cerebrospinal fluid testing. Patients testing negative with the panel are unlikely to be amyloid positive and should be investigated for other causes of cognitive decline.

Roche announced in July that the panel was granted breakthrough device designation by the FDA.